Biotech Kaleidoscope Converging in Hong Kong for the future of Biotech Worldwide

1

Foreword

BIOHK2020 will bring together the world’s leading,

established and most innovative stakeholders in biotech,

pharma and finance as they collaborate in exploring the

future of Hong Kong’s role as a Biotech hub for the

advancement of Biotech benefits worldwide.

2

Why Biotech in Hong Kong ?

Historically, the cyclical nature of biotech revolutions brought

a fresh surge of innovation every two decades.

Hong Kong is at the nexus of converging goals and visions

between key regional and global industry, finance, academic,

research and innovation sectors.

This is the right moment to capitalize on the Hong Kong

Special Administrative Region’s unique position as a strategic

global hub for biotech.

▪ President Xi Jinping directed state agencies to help

Hong Kong become an international innovation hub

▪ Hong Kong possesses extensive experience in

commercializing innovative technology for industrial

application and branding & marketing

▪ See more details in Appendix V

3

Hong Kong Being the Key Strategic Role

▪ World-class R&D capability

▪ World’s top three Financial Centers for Venture Capital

▪ Gateway to vast China market

▪ Strong International Investor Base

▪ See more in Appendix VI

4

Hong Kong Offers

5

Opening Ceremony Gala Dinner

Expo Conference

One2One Partnering Lan Kwai Fong Biotech Night

Luncheons Greater Bay Area Tour

Popular Science Day Road Show

Competition

Date: 19 - 22/08/2020 (Wed – Sat)

Venue: AsiaWorld – Expo Exhibition Hall (Tentative)

Exhibitors: Around 300

Speakers: Over 150

Expected visitors: 7,000

Highlights:

BIOHK2020 – Event Details

Investors Biological and

Startup Health and

medical industry

• Biotech Entrepreneurs

• CRO

• CMO

• Academia

• R&D Organizations

• Government

• Research Labs

• Leading Consultancy Services

• Science / Industrial Parks

• Incubation Centers

• Clinical & Education Trial Centers

• Diagnostics & Medical Devices

• Biopharmaceutical & Drug Developers

• Clinical Research & Lab Services

• Regenerative Medicine

• Agriculture and Fishery Biotechnology

• Bio manufacturing Platform Technologies

• Genomics / Genetics

• Marine Biotechnology

• Generic Drugs, API and Intermediates

• Smart Hospitals

• Investment, Legal and Financial Services

• And more

6

BIOHK2020 - Target Audience

Expo > Pitch and Connect

Pitch and Connect your company to the international

biotech scene and vast China market for trading and

collaboration opportunities

Conference > Share and Inspire

Share and Inspire through invaluable discussions about the

latest regional and international research findings and

industry trends

One2One Partnering > Promote and Establish

Promote and Establish your company as ‘one to watch’ in

the biotech marketplace by identifying and meeting

prospective partners

7

BIOHK2020 - Event Highlights

Reach the leading, established, most innovative and freshest voices in Big

Health Industry, Biotech, Drug Development and Pharma. Pitch and Connect

your company to the international biotech scene and vast China market for

trading and collaboration opportunities.

▪ Present your Brand and Innovations

▪ Reinforce Positioning

▪ Build Brand Awareness

▪ Extend Brand Reach

▪ Advertise to Target Market(s)

▪ Valuable Face-Time

▪ Connections with Related Parties

▪ Extend Visibility

▪ Expand Customer Base

▪ Business to Business Trading

8

Expo - Pitch and Connect

Enhance Your Awareness

A platform for in-depth discussions and mapping of the latest regional

and international industry and research findings and trends

9

Gain Unique Insights

Attain the Latest Know-how

Biotech seminars

Conference - Share and Inspire

Sessions will showcase leading thinkers, international scientists, entrepreneurs and

investors from diverse disciplines coming together to exchange research findings, ideas

and professional development experiences across a wide range of topics in interactive

sessions, panel discussions and podium talks.

We are expecting 1,000+ conference participants, including over 150 speakers across

multiple panel sessions

*Conference Themes see appendix IV

ZHAO Guo Ping Professor, Chinese Academy of

Sciences Synthetic Biology

Laboratory

YANG Huan Ming Co-founder, Director and Chairman

of BGI Group

ZHAN Qi Min Executive Vice President,

Peking University

WANG Yu Former Director General of Chinese Center for Disease Control and Prevention (China CDC)

LEUNG Chun-ying Vice Chairman, National Committee of the CPPCC

GRAY Nancy President & CEO, The Gordon Research Conferences

LI Charles Executive Director, Hong Kong Stock Exchange

GLASS David Vice President Research, Aging/Age-Related Disorders at Regeneron Pharmaceuticals, INC

10

ZHOU Guo Ying President & Professor, Shenzhen

International Institute for

Biomedical Research

YAN Nicholas Secretary , Innovation and Technology Bureau, HKSAR

Conference - Speakers (tentative)

Explore and secure collaborative partnerships and cross-border possibilities.

Promote and establish your company as “one to watch” in the biotech marketplace

by identifying and meeting prospective partners.

Network with industry practitioners, academicians, reputable biopharma firms and educational institutions

Spot your prospective partners – investors, analysts and partnering companies

Form valuable partnerships with leading biotech firms

Meet and greet with high-level executives

Build promising partnerships in a broad-spectrum marketplace

Investors have opportunities to extend business propositions to inventors

Explore Hong Kong as the home for your next business or start-up

11

One2One Partnering - Promote and Establish

BA Sujuan President and CEO,

National Foundation for Cancer Research

CHAN Kam Wan, Ronald Member (HK District),

Chinese Association of Hong Kong & Macao Studies

CHAN Sabrina Hong Kong Association of the

Pharmaceuticals Industry

CHAU Chi Wai, Wilton Chairman, Pan Asia Venture

Development Platform (PAVD)

CHEN Ping Founding Partner, Ausvic

Capital Limited

CHEN Wei Jie, Danny Investment Director, Affix Capital

HAU Desmond CEO, PANGENIA INC.

HSIAO Wen Luan, Wendy Professor, State Key Laboratory of

Quality Research in Chinese Medicine, Macau University of

Science and Technology

HU Charles Co-founder and Director of Clinical Development,

Incando Therapeutics Ltd.

JIANG Claire CEO of Queens (Shenzhen)

Biotechnology Co., Ltd.

JIANG Ru Hong Founder, CEO, President and Director,

ASC Therapeutics, Inc.

JIN Kewen Managing Partner / Co-founder of

Serica Capital

LAW Philip Partner, Audit & Assurance /

Market & Global Network

LE DEU Franck Senior Partner McKinsey &

Company - Head of Greater China

LEE Tin Lap Associate Professor, School of Biomedical Sciences, Faculty of Medicine, The Chinese University

of Hong Kong

LEUNG Yun Chung, Thomas Lo Ka Chung Charitable Foundation

Professor in Pharmaceutical Sciences

LI James President, Li Law Inc.

LI Ronald Director, Hong Kong node,

Ming Wai Lau Centre for Reparative Medicine

LI Ying Chair Professor of Neuroscience,

City University of Hong Kong

LIN Mindin CEO & Editor in Chief,

Global Bio & Investment Monthly

LO Kitty Chairman and CEO,

Finet Group Ltd.

LO Yuk Lam Winner of Pericles

International Prize 2019

LU Ming Hua Managing Partner, eChinaHealth, Inc.

MOK Kin Lun, John, Ir. Prof. Chairman of AML Holdings

Limited

NEARING Kimberly Managing Director, Cedrus Group

NGUYENPHUOC Donna PhuocPartner, SPARQ Capital

LI Xiao Yi, Benjamin CEO, Lee’s Pharmaceutical

Holdings Ltd.

LIU Andy CEO, CW Data Technologies

HAO Martha Business Consultant of Wise

Ally Holding Ltd.

JE Simon Founder & Chairman, Hong Kong

International Blockchain and Financial Association (HKIBFA)

LEUNG Chuen Yan Vice President, Portfolio

Management and Research

BIOHK2020 - Organizing Committee

12

CHUNG Pui Sing, John

Former superintendent, Hong Kong Police Force

**The list is still under updating

ORR Kevin Vice President, Winner

Medical Group

PAN Wendy, JD Goodwin Procter LLP

PEI Duan Qing Principle Investigator and Academic Director at the Guangzhou Institutes of Biomedicine and Health (GIBH),

Chinese Academy of Sciences

SEGERBLOM Bjorn Honorary Chairman and Hong Kong Representative, International Iberian

Nanotechnology Laboratory

SHANG Hai Long, Jesse Managing Director,

Sense Time Hong Kong

SHI Victor Chairman, Bayhelix

SUN Lin Hoffman, JD Bayhelix

SUN Nan Deputy Inspector, Shenzhen Association for Science and

Technology

TANG G Mark Managing Director, Good Health Capital (New York) and a Partner of Shanghai Healthcare Industry

Investment Fund, LP

TIAN Yao Lin CEO, Shenzhen Govita

Medical Laboratory

TSUI Victor, PE MSc Chief Manufacturing Officer,

Lee’s Pharmaceuticals

UHLEN Mathias President, European

Federation of Biotechnology

WAN Mu, Maki Immediate Past President of

Rotary Club Kowloon Golden Miles

WANG Jing Centre for Advanced

Measurement Science, National Institute of Metrology, China

WANG Yitao Director, Institute of

Chinese Medical Sciences

WONG Anny Member, Beta Beta Beta National

Biological Honor Society, USA

WONG Bing Lou Adjunct Professor, Department

of Biochemistry, Chinese University of Hong Kong

WONG Taam Chi Woon, Vivian Hon Professor, School of

Chinese Medicine, The University of Hong Kong

XIE Min, Robert CEO, Asia Investment Fund

Management Limited

YANG Haiding Executive Director and Medical Team Leader of

Cathy Capital

YANG Meng Su, Michael Head and Yeung Kin Man Chair

Professor, Department of Biomedical Sciences, City University of Hong Kong

YANG Ray Partner, Marathon Venture Partners

YANG Steve Chief Business Officer & Executive Vice President, WuXi AppTec Co., Ltd.

YE Zhao Yang Hai Kang Life Corporation Ltd.

YU Duncan President, MGI

YUNG Kin Lam, Ken Professor and Associate Head,

Faculty of Science, Hong Kong Baptist University

ZHOU Guo Ying, Grace Shenzhen International Institute for Biomedical

Research, President, Professor

ZHU Hua Vice President, The Hong Kong Chinese Enterprises Association

TSIM Wah Keung, Karl Director, Centre for Chinese

Medicine R &D

QIAN Pei Yuan David von Hansemann Professor of Science

YU Albert Chairman, BIOHK2020

Chairman, Hong Kong Biotechnology Organization Chairman, Guangdong-Hong Kong-Macao Greater Bay Area Biotechnology Alliance

ZHANG Jimmy Bayhelix

**The list is still under updating BIOHK2020 - Organizing committee

13

Conclusion

BIOHK2020 represents the beginning of a new era

in biotechnology in Hong Kong.

Join us at this event to witness the start of a new

wave of innovations that will benefit well-being

worldwide.

14

主辦機構 Organizers

全面展會管理 協辦機構 Co-organizers

15

鑽石贊助 Diamond Sponsors

16

特別支持機構

Special Supporting Organizations

支持機構

Supporting Organizations

17

國際夥伴 Global Partners

合作媒體

18

合作媒體 Media Partners

Please contact us and we will be happy to help you to plan

your BIOHK2020 experience!

HKBIO-ORG hkbio-org hkbio 19

Contact

Website: bio-hk.com Email: info@bio-hk.com Tel: (+852) 2799 7688 Fax: (+852) 2111 9762

Appendix

20

HKBIO, established in 2010 by reputable industry and esteemed academic representatives, is a non-profit

organization which continuously strives to promote Hong Kong as the biotech hub of Asia. HKBIO has

organized and sponsored several successful events in the past that highlighted the substantial potential of

Hong Kong’s Biotechnology sector.

BayHelix is an association of leaders of Chinese heritage in the global life sciences and healthcare

community. We aspire to shape the growth of the life sciences and healthcare industry around the Pacific

Rim and beyond, foster and create business opportunities, supply and nurture community leaders, and

network and share information and experience.

21

Appendix I: About the Organizers

HKBIO’s Past Events

2018 Hong Kong Biotech Horizons A mobile conference with the aim of promoting

biotech and connecting professionals from a cross section of industries to create a diverse network that can foster the biotech

industry’s development and innovation.

2017 Hong Kong Biotech Horizons “Global Congress on Biotechnology: Diagnostics

and Therapeutics” brought together communities of scientific researchers, technology developers and entrepreneurs seeking

progress in translational science.

HKBIO Horizon Series 12th International Conference on Brain Energy Metabolism-linked leading experts and young, emerging neuroscientists worldwide, all interested in diverse aspects of brain energy metabolism.

HKBIO Cancer Research Fund Dedicated to furthering the cause of preventing and curing cancer by promoting clinical cancer research in Hong Kong and China.

22

Appendix II: About HKBIO

Out of China’s 199 science parks, 111 are biotechnology parks, with 93 concentrated in the Guangzhou area. Some US$45 billion was invested in biotech companies in China between 2014-2017 – more than US$12 billion of it coming from Chinese venture capital and other private firms. China’s DNA sequencing market is expected to grow to 18.3 billion RMB by 2022 from 7.2 billion RMB last year, greatly surpassing the overall global market because of the country’s rising income and growing investments in health care infrastructure.

Hong Kong Stock Exchange’s biggest listing reform in 25 years (effective April 30th 2018) saw the establishment of a new Biotech chapter allowing biotech companies that are pre-revenue or insufficiently profitable to be listed — transforming Hong Kong into the world’s second largest biotechnology listing platform. Out of the top Asia-Pacific IPOs in 2016, four of the top five were China based biotech companies. Guangdong, Hong Kong and Macao – (key regions in the Greater Bay Area (GBA) established in 2017) promoted joint and coordinated regional economic development.

23

Appendix III: Biotechnology Trends in 2020

• Pharmacology

• Clinical Trials

• Genetic Engineering

• Food and Agriculture

• Medical Device Market Penetration

• Genome Editing and Gene Therapy

• International Strategic Perspectives

• Partnership with Hong Kong

• Global Cell Therapeutics Development and Regulatory Trends

• Biotech in Society and Culture

• Present and Future Bioethics

• Precision Medicine and Big Data

• Start-up Company

24

• Generics

• Stem Cell Research

• Digitization of Healthcare

• Intellectual Property Rights

• Roadshows

• Microbiome

• AI + Biotech

• New Therapies

• Cancer Therapies

• Block Chain + Biotech

• Glioblastoma

• 5G + Biotech

• Investment

• Marine Biotechnology

• One Belt One Road

• Antiaging

• Lab-on-a-chip

• Environmental Biotechnology

• Biotech IPO + HKEX

• Guangdong-HK-Macau GBA

• Immunotherapy

• Partner + Strategies

• China + USA Trade War

• Gene Editing

• And More

Appendix IV: Themes for the Conference

▪ Hong Kong Exchanges and Clearing Limited has enabled pre-revenue biotech companies to be listed on the Main Board – a milestone in stock market history

▪ Innovation and Technology (I&T) fund has financed over 540 biotech projects and aims to attract more world-class scientific research institutions & technology enterprises

▪ About 1,300 I&T companies and “incubates” have established themselves in the Hong Kong Science Park (HKSP) and Cyberport

▪ Currently, the city has approximately 250-300 biotech-related companies

▪ Hong Kong is a preferred destination for multinationals to set up offices and regional headquarters

▪ Hong Kong’s start-up scene has experienced phenomenal growth in recent years

▪ Several incubators and accelerators offer start-ups comprehensive incubation programs to promote the local biotech scene

25

Appendix V: Hong Kong Being the Key Strategic Role

▪ Active entrepreneurial ecosystem

▪ Free & open economy

▪ Gateway to vast China market

▪ Excellent fund-raising platform

▪ Established financial & legal systems

▪ Sound regulatory regime

▪ Transparent vetting process

▪ IP protection

▪ Business friendly taxes

▪ Innovation & Technology (I&T) fund

▪ Reputable quality control & assurance

26

Appendix VI: Hong Kong Offers

Thank You!

HKBIO-ORG hkbio-org hkbio

Contact

Website: bio-hk.com Email: info@bio-hk.com Tel: (+852) 2799 7688 Fax: (+852) 2111 9762

Scan and Find us